Since vascular endothelial growth factor (VEGF) helps in angiogenesis in tumors, another study by Sharma et al. studied the effectiveness of the VEGF receptor 2 (VEGFR2) inhibitor in renal cell carcinoma (RCC) patients and found that an inhibitor compound named SCHEMBL469307 is the most effective [15]. This evidence concerns the gene KDR and renal cell carcinoma.